Reverse payments in drug patent litigation settlements are one of several hot issues expected to affect the pharmaceutical industry this year. Reverse payment or pay-for-delay patent litigation settlements usually involve agreement between a branded drug company and a generic drug company to keep the generic off the market. NERA Vice President Dr. David Blackburn will join this Knowledge Group webcast to discuss current issues relating to patent settlement agreements and their impact on antitrust enforcement.

Learn more via The Knowledge Group website.